{"id":13898,"date":"2023-11-01T13:14:14","date_gmt":"2023-11-01T13:14:14","guid":{"rendered":"http:\/\/TheNextWeb=1401156"},"modified":"2023-11-01T13:14:14","modified_gmt":"2023-11-01T13:14:14","slug":"ai-nearly-twice-as-good-as-biopsy-at-assessing-rare-cancer","status":"publish","type":"post","link":"https:\/\/www.londonchiropracter.com\/?p=13898","title":{"rendered":"AI nearly twice as good as biopsy at assessing rare cancer"},"content":{"rendered":"\n

AI<\/a> could be nearly twice as accurate as biopsies at assessing the aggressiveness of some rare types of cancer, a new study suggests. According to researchers this could save the lives of thousands of patients.<\/p>\n

A research team from the Royal Marsden NHS Foundation Trust and the Institute for Cancer Research (ICR) focused on retroperitoneal sarcoma \u2014 a form of soft tissue sarcoma that develops in the back of the abdomen.<\/p>\n

\u201cThere is an urgent need to improve the diagnosis and treatment of patients with retroperitoneal sarcoma, who currently have poor outcomes,\u201d said Dr Amani Arthur, first author of the study.<\/p>\n

\u201cThe disease is very rare \u2014 clinicians may only see one or two cases in their career \u2014 which means diagnosis can be slow. This type of sarcoma is also difficult to treat as it can grow to large sizes and, due to the tumour\u2019s location in the abdomen, involve complex surgery.\u201d<\/p>\n

To develop and train an AI algorithm, the researchers used CT scans of 170 patients suffering from the two most common types of retroperitoneal sarcoma: leiomyosarcoma and liposarcoma. Then, they tested the algorithm on a set of 89 patients across Europe and the US.<\/p>\n

\n
<\/p>\n

Get your ticket NOW for TNW Conference – Super Earlybird is almost sold out!<\/p>\n

Unleash innovation, connect with thousands of tech lovers and shape the future on June 20-21, 2024.<\/p>\n

<\/a><\/div>\n<\/div>\n

The technology accurately assessed the aggressiveness of the tumours 82% of the time, while biopsies were correct in only 44% of the cases. The AI model was also able to predict the type of 84% of the sarcomas tested, compared to radiologists who could diagnose 65% of the cases.<\/p>\n

\"Professor
<\/i><\/a>Study lead Professor Christina Messiou,Consultant Radiologist at the Royal Marsden NHS Foundation Trust and Professor in Imaging for Personalised Oncology at the Institute of Cancer Research. Credit: ICR<\/figcaption>